Satellos Bioscience Inc.

MSLE Nasdaq SEC CIK 1421642
Follow Satellos Bioscience Weekly email: filings, results

Financials

Reported figures only · latest: fiscal 2025 USD · IFRS
Net income −$24.9M −20.5% vs prior year
EPS, diluted −$1.70 +21.3% vs prior year
Operating cash flow −$23.6M −29.3% vs prior year
Operating income −$26.5M −29.7% vs prior year
Net income by fiscal year
−$20.6M
−$24.9M
FY24 FY25

Source: SEC XBRL filings · latest filing